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phenotypic and transcriptomic 
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Myeloid-derived suppressor cells (MDSCs) are key players in immune evasion, tumor progression and 
metastasis. MDSCs accumulate under various pathological states and fall into two functionally and 
phenotypically distinct subsets that have been identified in humans and mice: polymorphonuclear 
(PMN)-MDSCs and monocytic (M)-MDSCs. As dogs are an excellent model for human tumor 
development and progression, we set out to identify PMN-MDSCs and M-MDSCs in clinical canine 
oncology patients. Canine hypodense MHC class II−CD5−CD21−CD11b+ cells can be subdivided 
into polymorphonuclear (CADO48A+CD14−) and monocytic (CADO48A−CD14+) MDSC subsets. The 
transcriptomic signatures of PMN-MDSCs and M-MDSCs are distinct, and moreover reveal a statistically 
significant similarity between canine and previously published human PMN-MDSC gene expression 
patterns. As in humans, peripheral blood frequencies of canine PMN-MDSCs and M-MDSCs are 
significantly higher in dogs with cancer compared to healthy control dogs (PMN-MDSCs: p < 0.001; 
M-MDSCs: p < 0.01). By leveraging the power of evolution, we also identified additional conserved 
genes in PMN-MDSCs of multiple species that may play a role in MDSC function. Our findings therefore 
validate the dog as a model for studying MDSCs in the context of cancer.
Myeloid-derived suppressor cells (MDSCs) comprise a functionally distinct phenotype of innate immune cells 
that play an important role in the immune dysregulation characteristic of cancer1–4. Recent years have witnessed 
an increasing recognition of the clinical relevance of MDSCs. Accumulation of these cells has been reported in 
practically all human cancers, and increased frequencies of circulating MDSCs have been correlated with poor 
prognosis, offering a biomarker of clinical outcome in a variety of cancer histotypes5.
Generated by pathological subversion of polymorphonuclear (PMN) and monocytic (M) differentiation and 
activation pathways in the context of chronic inflammatory conditions and cancer, MDSCs represent a heteroge-
neous population of two major subsets, PMN-MDSCs and M-MDSCs, which are identified by a combination of 
multiple lineage markers. In mice, PMN-MDSCs are defined as CD11b+Ly6G+Ly6Clo cells, while M-MDSCs are 
defined as CD11b+Ly6G−Ly6C+ cells. In humans, PMN-MDSCs are characterized as CD11b+CD14−CD15+ or 
CD11b+CD14−CD66b+ cells, while M-MDSCs are CD11b+CD14+HLA-DR−/lo CD15− cells. A third group com-
prising immature myeloid progenitors has also been described as Lin−(CD3/14/15/19/56)/−HLA-DR−/CD33+ 
cells4,6–8.
Although a number of pivotal mechanistic studies on the pathobiology of cancer have been performed using 
the mouse as a model for humans, there is an unmet need for animal models that better recapitulate human 
cancer to investigate novel therapeutic targets, including cellular targets such as MDSCs9,10. Canine malignancies 
have already been recognized as strong comparative models for several human cancers11,12. Dogs spontaneously 
develop a variety of tumors that share many features with human cancer, including clinical, pathological, and 
molecular characteristics11–13. Furthermore, dogs have an intact immune system that allows faithful recapitulation 
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of the tumor microenvironment and circulating regulatory T cells of human patients11,14. Of note, a number of 
drugs utilized in veterinary medicine were originally developed for human use, further emphasizing the bilateral 
benefits of the One Health approach to both dogs and humans alike11–13. The contributions of the comparative 
oncology field thus far therefore raise the question of whether dogs with spontaneous tumors may also shed 
insight into MDSC biology.
To date, two seminal studies described MDSCs in a variety of cancer histotypes in dogs15,16, but many 
questions remain unanswered. Although these studies identified the existence of this suppressive myeloid cell 
population in the peripheral blood of dogs, this early work did not characterize the two subsets of MDSCs, an 
essential prerequisite to their investigation in canine models of human cancer. The current study therefore set 
out to characterize MDSC subsets in tumor-bearing dogs, hypothesizing that their cellular phenotype and tran-
scriptomic signatures would reflect those of both human and murine MDSC subsets. We identified two distinct 
myeloid cell populations in the circulating blood of tumor-bearing dogs with similar phenotypic, functional, and 
transcriptomic characteristics to human and murine PMN-MDSCs and M-MDSCs. Capitalizing on the power 
of a comparative evolutionary approach, we characterized the cellular and transcriptomic phenotype of both 
PMN-MDSCs and M-MDSCs. We identified five transcripts that are expressed at high levels by canine, human, 
and murine PMN-MDSCs, yielding novel insights into fundamentally conserved PMN-MDSC gene expression 
patterns spanning multiple evolutionary taxa.
Materials and Methods
study population and sample collection. Peripheral blood samples were collected from dogs with can-
cer or non-neoplastic inflammatory diseases recruited at the Royal Veterinary College (RVC), North Downs 
Specialist Referrals (NDSR), and Fitzpatrick Referrals (Oncology and Soft Tissue; FR) in the United Kingdom, 
and the School of Veterinary Medicine at the University of Pennsylvania (Penn Vet) in the United States of 
America. Healthy control dogs were also recruited at the RVC and Penn Vet, defined by an absence of clinically 
significant findings following a detailed history and physical examination performed by a veterinarian or veter-
inary nurse. Inflammatory control dogs included those with infectious or immune-mediated disease, in which 
neoplasia was ruled out by relevant diagnostic tests, including imaging of the thorax and/or abdomen. Forty-one 
tumor-bearing, 37 inflammatory, and 31 healthy dogs were recruited at the RVC; 51 tumor-bearing dogs were 
recruited at NDSR; five tumor-bearing dogs were recruited at FR; and 21 tumor-bearing, three inflammatory, and 
25 healthy dogs were recruited at Penn Vet.
Tumor burden was classified as follows: For B cell lymphoma, patients were grouped based on the World 
Health Organization staging system, with stage I/II defined as low burden and stage III-IV defined as high bur-
den. In patients with solid non-lymphoid tumors, a low burden tumor was defined as one whose sum of the 
longest diameters of the lesions was smaller than 5 cm without evidence of lymph nodal and/or distant metastasis. 
A high burden tumor was defined as one whose sum of the longest diameters of lesions was greater than 5 cm, 
with or without evidence of lymph nodal and distant metastasis. This study was approved by the RVC’s Clinical 
Research Ethical Review Board (URN 2014 1285), the University of Pennsylvania’s Institutional Animal Care and 
Use Committee, and Penn Vet’s Privately Owned Animal Protocol Committee; all samples were collected and 
processed in accordance with the relevant guidelines and regulations. A peripheral blood sample was collected 
aseptically from each dog from the jugular or lateral saphenous vein into one or more EDTA tubes after informed 
consent was granted by the owner of each dog. All blood was processed within 48 hours of collection.
preparation of pBMCs and pMN cell isolation. MDSCs were isolated from the mononuclear frac-
tion following density gradient centrifugation as follows. Blood was diluted with an equal volume of sterile 
Dulbecco’s Phosphate-Buffered Saline (DPBS; Corning Cellgro, Tewksbury, MA, USA) containing 2% v/v fetal 
bovine serum (FBS; Hyclone, Logan, UT, USA), and gently layered over Histopaque-1077® (Sigma-Aldrich, 
St. Louis, MO, USA). Samples were centrifuged at 400 g for 30 minutes, with acceleration and deceleration set 
to zero. The peripheral blood mononuclear cell (PBMC) layer was washed twice with Roswell Park Memorial 
Institute (RPMI)-1640 medium (Life Technologies, Carlsbad, CA, USA) containing 10 mM HEPES, 2 mM 
L-glutamine (Life Technologies), 100 units/mL penicillin-streptomycin (Life Technologies), 10% FBS, and 50 μM 
2-mercaptoethanol (Life Technologies) (complete medium), before re-suspension in DPBS containing 10% v/v 
FBS and staining for analytical flow cytometry or flow-assisted cell sorting (FACS™). PMNs were isolated from 
the remaining cell fraction after removal of the mononuclear cells and treatment with Red Blood Cell (RBC) Lysis 
Buffer (Multi-Species; Thermo Fisher Scientific, San Diego, CA, USA) according to the manufacturer’s instruc-
tions. After RBC lysis, cells were washed and re-suspended in DPBS-10% v/v FBS for staining.
Flow cytometry and cell sorting. For MDSC analysis, PBMCs were labelled with a cocktail of mono-
clonal antibodies (mAb) for 30 minutes at 4 °C according to the respective manufacturer’s protocol. The cock-
tail comprised APC-conjugated anti-dog MHC II (clone YKIX334.2; Thermo Fisher Scientific), PE-conjugated 
anti-dog-CD5 (clone YKIX322.3; Bio-Rad, Hercules, CA, USA), PE-conjugated anti-dog CD21 (clone CA2.1D6; 
Bio-Rad), PE-Alexa647-conjugated anti-human CD14 (clone TUK4; Bio-Rad), PE-Cy7-conjugated anti-dog 
PMN leukocyte antigen (antigen unknown, clone CADO48A; University of Washington, Pullman, WA, USA), 
and Alexa Fluor 488-conjugated anti-mouse CD11b (clone M1/70; Thermo Fisher Scientific). PMNs from 
tumor-bearing or healthy dogs were identified as CADO48A+ cells isolated from the RBC-containing pel-
let. Antibody-labeled cells were washed twice and re-suspended in DPBS-10% v/v FBS, then incubated with 
4′,6-diamidino-2-phenylindole (DAPI; BioLegend, San Diego, CA, USA) at room temperature for 10 minutes 
prior to analysis.
Flow cytometric data were acquired using a FACSCanto II flow cytometer (Becton-Dickinson (BD); Franklin 
Lakes, NJ, USA) and analyzed using FlowJo® software, version 10.3 (Tree Star, Ashland, OR, USA). Cell sorting was 
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performed using a BD FACSAria III or a BD FACSAria Fusion in the case of dogs recruited at the RVC, and a BD 
FACSAria II in the case of dogs recruited at Penn Vet. Monocytes were isolated from the PBMC layer and identi-
fied as CD5−CD21−MHCII+CD11b+CD14+ cells (H MONOs, healthy donor; C MONOs, tumor-bearing donor), 
while PMNs were isolated from the hyperdense pellet and identified as CD5−CD21−MHCII−CD11b+CADO48A+ 
cells (H PMNs, healthy donor; C PMNs, tumor-bearing donor). MDSCs were isolated from the PBMC layer, with 
M-MDSCs identified as CD5−CD21−MHCII−CD11b+CD14+CADO48A− cells, and PMN-MDSCs identified as 
CD5−CD21−MHCII−CD11b+ CD14−CADO48A+ cells.
Analysis of MDSC frequencies. Frequencies of MDSCs isolated from peripheral blood were reported as 
median [25th, 75th percentiles]. A linear mixed effects model was used to assess differences between PMN-MDSCs 
and M-MDSCs, and among tumor-bearing, inflammatory disease and healthy dogs, and specific contrasts were 
constructed to compare high and low burden tumors. Frequencies of MDSCs were log transformed, ln (0.1+ 
frequency), prior to the analysis.
Cytocentrifuge spin preparation. A Shandon Cytospin 2 centrifuge (Sandon Southern Products Ltd., 
Astmoor, UK) was used to deposit cells onto Shandon cytoslides (Thermo Sandon Limited, UK). The slides were 
dried, stained with Modified Wright’s (Siemens Hematek Stain Pak, NY, USA) using a Hematek automated stainer 
(Siemens, Tarrytown, NY, USA) and examined with a BX50 microscope (Olympus, Tokyo, Japan). Images were 
captured with a SC50 camera and edited with CellSens® software (Olympus; Southend-on-Sea, UK).
electron microscopy and eR dilation scoring. PMN-MDSCs and PMNs were isolated from two 
tumor-bearing dogs, while monocytes were isolated from one tumor-bearing dog. Cells were fixed in 2% w/v 
paraformaldehyde and 1.5% w/v glutaraldehyde in 0.1 M sodium cacodylate for 24 hours at 3 °C. After washing 
in 0.1 M sodium cacodylate twice, each time for 30 minutes, cells were embedded in 2% w/v agarose. Specimens 
were then dehydrated in a graded ethanol-water series, before being immersed in agar resin. The specimens were 
left in fresh agar resin for eight hours, before being hardened for 48 hours at 60 °C. Representative areas were 
selected and ultra-thin sections cut at 70–80 nm using a diamond knife in an Ultracut S microtome (Reichert 
Technologies; Munich, Germany). Sections were collected on 200 mesh copper, stained with lead citrate, and 
viewed with a 1010 transition electron microscope (Jeol; Peabody, MA, USA). Images were recorded using an 
Orius CCD camera (Gatan; Pleasanton, CA, USA). Our approach was adopted from a published protocol17, 
reviewing at least 100 cells per sample. The proportion of visible cytoplasmic area per cell containing dilated 
ER was estimated, scores 1, 2, and 3 representing areas of up to one third, more than one third but less than two 
thirds, and more than two thirds respectively.
t cell suppression assay. Proliferation assays were performed in duplicate, when cell numbers allowed, in 
96-well, flat bottom culture plates pre-coated with anti-dog CD3 mAb (clone CA17.2A12; Bio-Rad), applied as 
a 5 µg/ml solution for two hours at 37 °C before washing. An aliquot of 100,000 healthy PBMCs was deposited 
into each well, alone or with either PMNs from tumor-bearing or healthy dogs, or PMN-MDSCs, at a 1:1 ratio. 
Anti-CD28 mAb (clone 1C6; ThermoFisher Scientific) was added to each well at a final concentration of 2.5 µg/ml. 
Plates were incubated at 37 °C for 72 hours in an atmosphere of 5% carbon dioxide, before staining of the cells for 
analytical flow cytometry on a BD FACSCanto II. Responder PBMCs and co-cultured cells, if applicable, were 
harvested and stained with eBioscience fixable viability dye (eFluor780, Thermo Fisher Scientific) for 20 minutes 
at room temperature, followed by a 30 minute incubation at 4 °C with a cocktail comprising of anti-dog CD5 (as 
above) and AlexaFluor647-conjugated anti-dog CD8 mAb (YCATE55.9; Bio-Rad). The cells were then fixed and 
permeabilized (Foxp3/Transcription Factor Staining Buffer Set; Thermo Fisher Scientific) prior to staining with 
pacific blue-conjugated anti-mouse/rat Ki-67 (SolA15; Thermo Fisher Scientific) for 30 minutes at 4 °C. A linear 
mixed effects model was used to analyze suppression assay results. Normality of the residuals were inspected 
using histograms and Shapiro-Wilk normality test. The analyses were carried out in R using lme4 (Version 
1.1.17), lmerTest (Version 3.0.1) and multcomp (Version 1.4.8) packages.
RNA extraction. FACS™ was used to isolate MDSC subsets from dogs with cancer, alongside PMNs and 
monocytes from both tumor-bearing and healthy dogs. Cells were centrifuged at 600 g for five minutes at 4 °C, 
re-suspended in RNA-Bee (Amsbio; Abingdon, UK), and stored at −80 °C until extraction. RNA extraction was 
performed using the Direct-zol RNA MicroPrep Kit (Zymo Research; Irvine, CA, USA) according to the manu-
facturer’s protocol. RNA was stored at −80 °C.
Library preparation and sequencing. RNA sequencing (RNA-Seq) libraries were prepared and 
sequenced by the Oxford Genomics Centre at the Wellcome Centre for Human Genetics, using the protocol for 
low-input RNA library preparation with Smart-seq218. Briefly, full-length cDNA was generated from 0.6–1.0 ng 
of total RNA. Illumina libraries were prepared from cDNA samples using the Nextera XT DNA Library Prep 
Kit (Illumina, San Diego, CA, USA) and PCR-amplified with in-house indexing primers19. All samples were 
sequenced on the Illumina HiSeq4000 platform, with 75 bp paired-end sequencing.
Read processing and expression quantification. Reads were trimmed for Nextera, Smart-seq2 and 
Illumina adapter sequences using skewer-v0.1.12520. Trimmed read pairs were aligned to a modified reference 
genome comprising the canine genome Canis familiaris CanFam3.1 and External RNA Controls Consortium 
(ERCC) spike-in mix sequences (ThermoFisher), using HISAT2 version 2.0.421 with default parameters. 
Duplicate reads were marked using MarkDuplicates.jar implemented in Picard tools v1.92 (http://broadinstitute.
github.io/picard/, February 2018). Binary Alignment Map (BAM) alignments were name-sorted with Samtools 
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version 1.122. Reads mapping uniquely to exons of genes annotated in Ensembl release 8123 were counted using 
featureCounts24 implemented in subread-v1.525.
Data quality control and differential expression analysis. Alignment metrics were calculated using 
CollectRnaSeqMetrics from Picard tools for both full BAM files, and BAM files with potential PCR duplicates 
were marked. Additional metrics were calculated and downstream analysis performed with custom R scripts 
using R core tools26, v3.1.0 and v3.4.2 respectively. Differentially expressed genes were identified for each compar-
ison using edgeR v3.20.427,28. Genes with significant differential expression and a false discovery rate (FDR) ≤0.05 
in each comparison were used for gene-ontology enrichment analysis using GOseq v1.22.029.
Gene enrichment comparisons were plotted on Venny 2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny/). 
Ingenuity Pathway Analysis (IPA) (Qiagen, Hilden, DE) was used for interpretation of the RNA-Seq data, using 
differentially expressed genes whose fold change (FC) ≥2 and FDR ≤ 0.05. In pathway enrichment analysis, 
p-values were calculated by right-tailed Fisher’s exact tests, which indicate the probability of association of mol-
ecules from the dataset with the canonical pathway by random chance alone. The Z-score was used to quantita-
tively compare the dataset with the canonical pathway patterns, taking into account the activation state of one 
or more key molecules when the pathway was activated, as well as the molecules’ causal relationships with each 
other. Pathways with p ≤ 0.05 in the enrichment analysis were considered enriched, while the activation states 
of pathways were determined when |Z-score| ≥ 2. Heatmaps illustrating the RNA-Seq dataset were created in 
Morpheus (https://software.broadinstitute.org/morpheus/, Broad Institute), using only those genes expressed 
in every patient and cell type with transcripts per million (TPM) values of over 10. Clustering of the rows and 
columns in the heatmap comparing transcriptomic signatures of different cell types was performed using the 
1-Spearman rank correlation metric as the measure of dissimilarity. Box-and-whisker plots were drawn and all 
transcriptomic analyses were undertaken in R v3.4.2 (The R Foundation, Vienna, AT), using R packages lattice 
v0.20.35 and ggplot2 v2.2.1. R was also used to create principal component analysis (PCA) and volcano plots.
Reverse transcriptase-quantitative PCR. RNA was converted into cDNA using the High-Capacity 
RNA-to-cDNA Kit (ThermoFisher Scientific), following the manufacturer’s protocol. RT-qPCR reactions were 
prepared according to the manufacturer’s protocol, using TaqMan Fast Advanced Master Mix (ThermoFisher 
Scientific). Primers, all purchased from ThermoFisher Scientific, recognized hypoxanthine phosphoribosyl-
transferase 1 (HPRT1; Cf02690456_g1), ribosomal protein L13a (RPL13A; Cf04947268_gH), lactoferrin (LTF; 
Cf02649397_m1), lipocalin 2 (LCN2; Cf02667820_m1), cathelicidin (CAMP; Cf02626391_m1), erythrocyte 
band protein EPB41L3 (Cf02682517_m1), and the matrix metalloprotease MMP8 (Cf03649138_u1). The reac-
tions were run on a Quant Studio 6 Flex Real-Time PCR System (ThermoFisher Scientific), using recommended 
cycle conditions for TaqMan Fast Advanced Master Mix: hold at 50 °C for 2 minutes, hold at 95 °C for 20 seconds, 
and 40 cycles of denaturing for 1 second at 95 °C, followed by annealing and extending for 20 seconds at 60 °C.
No-template and no-reverse transcriptase reactions were used as controls, verifying the specificity of the assay. 
PCR efficiency was determined by testing the primers across a 4 or 5-fold logarithmic dilution of cDNA template. 
The plot of Cq versus template concentration was used to calculate the slope, and amplification efficiency (E) of 
individual primers was determined by the equation = −E 10 1/slope. The most stable reference genes, HPRT1 and 
RPL13A, were selected from a set of tested candidate reference genes as determined by the qbase + (Biogazelle) 
implementation of geNorm. Relative expression of genes was determined by Pfaffl’s model,
=
Δ −
Δ −
( )
Relative Expression
E
(E )
control sample
control sample
target
Cq ( )
ref
Cq ( )
target
ref
where Etarget is the efficiency of the target gene primer, Eref is the efficiency of the reference gene primer, ΔCqtarget 
is the difference in Cq of C PMNs and PMN-MDSCs for the target gene transcript, and ΔCqref is the difference in 
Cq of C PMNs and PMN-MDSCs for the reference gene transcript.
Cross-species comparisons. Data used for the cross-species analysis of PMN-MDSCs were obtained from 
the authors30 and NCBI (GEO accession number GSE43254)31. Differential gene expression for murine data was 
evaluated in GEO2R (NCBI), using the Benjamin-Hochberg multiple comparisons correction and auto-detecting 
log transformation. Gene lists used to create Venn diagrams excluded genes with absolute FC < 2 and FDR > 0.05. 
Only those genes expressed in all three species were included in similarity score calculation. Gene lists for each 
species were ranked in the following order: FDR ≤ 0.05 and FC ≥ 2, FDR ≤ 0.05 and FC ≤ −2, FDR ≥ 0.05 and 
FC ≥ 2 and FDR ≥ 0.05 and FC ≤ −2, so that most significantly upregulated genes were at the top and the most 
significantly downregulated genes were at the bottom of the list, followed by non-statistically significant genes. 
Each cell-type-specific signature from dog was compared with respective human and murine signatures using 
the R package OrderedList v1.48.032. This tool determines the number of shared elements in the first n elements 
of two lists and calculates a final similarity score, genes receiving more weight the closer they are to the top or 
bottom of the list. Similarity scores for n = 500 are reported. To assess the statistical significance of the similarity 
scores, the observed values were compared with a null distribution obtained by reshuffling the genes.
Pathway enrichment analysis was performed in IPA for the 44 commonly upregulated genes in human and 
canine PMN-MDSCs. Those pathways containing two or more genes (from the list of 44 shared genes) showing 
the strongest statistical significance were reported.
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Figure 1. Two phenotypically distinct subsets of hypodense myeloid cells can be isolated from canine 
peripheral blood. (a) Gating strategy used to identify putative PMN-MDSC (CADO48A+CD14−) and 
M-MDSC (CADO48A−CD14+) subsets in the peripheral blood of dogs. Shown are representative examples 
from dogs that have PMN-MDSC frequencies (relative to total PBMCs) similar to the median values of all 
dogs in that group (cancer, top, median: 2.58%; inflammatory, middle, median: 1.33%; healthy, bottom, 
median: 0.78%). (b) Cytocentrifuge preparations of flow-sorted MDSCs with PMN (top) and MONO (bottom) 
morphology. Scale bars: 10 μm. (Images collected by B.S.). (c) Images obtained through electron microscopy 
analysis of cell morphology, with arrows denoting prominent ER. Scale bars: 500 nm, magnification 9700x, 
featured square magnification 3600x. (Images collected by M.T.). (d) C PMNs, PMN-MDSCs, C MONOs, and 
M-MDSCs were scored for the presence of dilated ER; the bar chart depicts the proportion of cells with each ER 
dilation score. (e) Box-and-whisker plots depicting frequency of PMN-MDSCs in peripheral blood of healthy 
and inflammatory controls as well as tumor-bearing dogs, grouped by cancer subtype (HM: hematopoietic 
mesenchymal/mesodermal, NHM: non-hematopoietic mesenchymal/mesodermal, EPI: epithelial) and burden 
(low vs high). Frequencies are expressed as a percentage of total PBMCs. A capital letter denotes that the two 
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Results
Hypodense myeloid cell subsets accumulate in the peripheral blood of tumor-bearing dogs. 
To test the hypothesis that phenotypically distinct hypodense myeloid cell subsets resembling PMN-MDSCs and 
M-MDSCs exist in canine blood, PBMCs were stained with a mAb panel reflective of the phenotypic markers 
used to identify human MDSC subsets4,6,33. Using a cascaded gating strategy as shown in Fig. 1a, hypodense 
myeloid cells resembling MDSCs, i.e. CD5−CD21−MHCII−CD11b+ cells, were stratified into two distinct sub-
sets – one expressing CADO48A+, a canine specific neutrophil marker (putative PMN-MDSCs), and the other 
expressing CD14+ (putative M-MDSCs). Morphologic examination of cytocentrifuged preparations of these two 
myeloid populations supported their putative identity as MDSC subsets: the CADO48A+ cells resembled PMNs 
with segmented nuclei, while the CD14+ cells resembled monocytes with a large nucleus and vacuolar cytoplasm, 
reflecting MDSC images previously published in the human and murine literature34–37 (Fig. 1b). Parental gating 
analyses were also consistent with our view that these cells were MDSCs (Supplementary Fig. S1A).
We next interrogated the ultrastructure of these myeloid subsets, in particular to ask whether they exhibited 
features of ER stress, manifested through dilation, as has been described in human MDSC subsets17. Putative 
PMN-MDSCs, putative M-MDSCs, PMNs and MONOs were isolated from tumor-bearing dogs and scored for 
the presence of dilated ER. Although a small proportion of cancer PMNs and MONOs had mild ER dilation (see 
arrows), with a score of 1, only the putative PMN-MDSCs and putative M-MDSCs exhibited moderate to marked 
ER dilation (see arrows), with scores of 2 or 3 (Fig. 1c,d), further supporting their identity as MDSCs.
Since increased frequencies of MDSC subsets have been described in human cancer patients and 
tumor-bearing mice compared to individuals with non-neoplastic inflammatory diseases and healthy controls, we 
set out to determine whether this pattern could be observed in dogs. First, a global comparison of CADO48A+ and 
CD14+ CD5−CD21−MHCII−CD11b+ myeloid cell frequencies (relative to total PBMCs) in the peripheral blood 
of tumor-bearing versus control dogs revealed an increased frequency of the CADO48A+ myeloid population 
(putative PMN-MDSCs; 2.53% [0.93, 4.94]) in comparison to healthy dogs (0.78% [0.13, 1.95]; p = 1.8 × 10−12) 
and those with non-neoplastic inflammatory diseases (1.33% [0.31, 2.75]; p = 0.0024) (Supplementary Fig. S1B). 
The CD14+ myeloid population (putative M-MDSCs) was also increased in tumor-bearing dogs (0.20% [0.06, 
0.57]) when compared to healthy control dogs (0.14% [0.05, 0.24]; p = 0.018) but not those with inflammatory 
disease (0.28% [0.12, 0.64]; p = 0.72) (Supplementary Fig. S1C).
Tumor-bearing dogs were then grouped according to broad tumor histotype (hematopoietic mesenchy-
mal/mesodermal, HM; non-hematopoietic mesenchymal/mesodermal, NHM; and epithelial, EPI) and based 
on tumor burden (low versus high burden) (Fig. 1e). In the case of the putative PMN-MDSCs, dogs with high 
burden HM tumors had higher median frequency than those with low burden HM tumors (3.20% [1.46, 6.32] 
versus 1.20% [0.69, 1.91]; p = 0.0086); statistically significant differences in frequency with burden were not pres-
ent for NHM tumors (1.69% [1.48, 4.79] versus 0.89% [0.72, 1.47]; p = 0.17) or EPI tumors (2.81% [1.37, 5.30] 
versus 1.50% [0.40, 6.31]; p = 0.28). Furthermore, dogs with a high tumor burden, regardless of histotype, had 
higher frequencies of these cells than healthy control dogs (HM: 3.20% [1.46, 6.32] versus 0.78% [0.13, 1.95], 
p = 1.5 × 10−13; NMH: 1.69% [1.48, 4.79] versus 0.78% [0.13, 1.95], p = 0.0034; EPI: 2.81% [1.37, 5.30] versus 
0.78% [0.13, 1.95], p = 5 × 10−6). Dogs with high burden HM or EPI tumors also had higher frequencies of the 
putative PMN-MDSCs than those of non-neoplastic inflammatory control dogs (HM: 3.20% [1.46, 6.32] ver-
sus 1.33% [0.31, 2.75], p = 0.00015; EPI: 2.81% [1.37, 5.30] versus 1.33% [0.31, 2.75], p = 0.0091, respectively). 
Of dogs with low burden tumors, only those bearing EPI tumors had higher frequencies of these cells than 
healthy control dogs (1.50% [0.40, 6.31] versus 0.78% [0.13, 1.95], p = 0.00098), but not inflammatory control 
dogs (1.50% [0.40, 6.31] versus 1.33% [0.31, 2.75], p = 0.16). Similar differences were not apparent for putative 
M-MDSCs (Supplementary Fig. S1D). However, dogs with high burden as well as low burden EPI tumors had 
higher frequencies of putative M-MDSCs than healthy control dogs (high burden: 0.31% [0.09, 0.87] versus 0.14% 
[0.05, 0.24], p = 0.037; low burden: 0.21% [0.15, 0.86] versus 0.14% [0.05, 0.24], p = 0.01).
In toto, these findings added further credibility to our hypothesis that the myeloid subsets we identified were 
indeed canine MDSC populations. However, legitimately labeling the cells as MDSCs would require evidence of 
their suppressive activity, prompting functional studies in vitro. For this purpose, we focused on the most numer-
ous of the two myeloid populations, i.e. the CADO48A+ cells that were putatively PMN-MDSCs, to ensure that 
we would have sufficient cells available to allow reliable suppression assays to be performed.
Hypodense CADO48A+ myeloid cells suppress CD8+ t cell proliferation in vitro. The CADO48A+ 
cells suppressed polyclonal CD8+ T cell proliferation as indicated by reduced Ki-67 expression (Fig. 2a), confirm-
ing their functional credentials as regulatory cells. PMNs isolated from tumor-bearing dogs showed no statisti-
cally significant suppressive activity (Fig. 2b). Our findings therefore confirmed the suppressive function of the 
CADO48A+ cells. Given both the phenotypic resemblance of these cells to PMN-MDSCs and their regulatory 
credentials, we were able to confirm their identity as PMN-MDSCs. We hypothesized that the CD14+ myeloid 
cells would also be suppressive, and thus tentatively labeled them as M-MDSCs; however, in the absence of evi-
dence of suppressive function, this designation remained speculative. Further interrogation of the molecular 
phenotype of the myeloid cells followed, drawing comparisons with both human and murine MDSCs.
groups are significantly different with p < 0.001; a lowercase letter denotes a significant difference with p < 0.01. 
In the case of all box-and-whisker plots, the box shows the respective 25th and 75th percentiles, the line 
indicates the median value, and the whiskers stretch from the lowest to the highest data points still within 1.5 
times the interquartile range of the respective lower and upper quartiles. Red values indicate patient frequencies 
that are off-scale. Each dot represents a single dog.
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Canine MDSC subsets show distinctive transcriptomic signatures. We undertook RNA-Seq of 
PMN-MDSCs (n = 8), M-MDSCs (n = 5), PMNs (n = 9), and MONOs (n = 8) isolated from tumor-bearing 
dogs, and PMNs (n = 5) and MONOs (n = 3) isolated from healthy dogs. Principal component analysis of the 
samples from all dogs suggest the distinctive transcriptomes of the MDSC subsets, which were more closely 
related to their respective conventional populations than to each other (Fig. 3a). Similar conclusions were derived 
from a heatmap analysis comparing PMN-MDSCs, M-MDSCs, PMNs isolated from healthy (H PMN) and 
tumor-bearing patients (C PMN), and MONOs isolated from healthy (H MONO) and tumor-bearing patients (C 
MONO), supporting the finding that putative M-MDSCs, C MONOs, and H MONOs were more closely related 
to each other than to PMN-MDSCs, C PMNs, and H PMNs, which occupied a separate cluster (Fig. 3b). Within 
each cluster the respective MDSC subset was distinct, confirming its molecular credentials as a separate popula-
tion from the adjacent conventional cells.
On deeper scrutiny of the different patterns of gene expression between cell populations, we observed that 
canine PMN-MDSCs differentially expressed a number of transcripts associated with MDSC function compared 
to C PMNs, including those encoding the matrix metalloproteases MMP8 and MMP9, nitric oxide synthase 
2 (NOS2), NADPH oxidase 2 (NOX2), myeloperoxidase (MPO), cyclooxygenase 1 (COX1), the chemokine 
CXCL17, prostaglandin E synthase (PTGS1) and prostaglandin E receptor 2 (PTGER2) (Fig. 3c). A number of 
transcripts previously not attributed to PMN-MDSC function were also expressed at higher levels, including 
those encoding succinate receptor 1 (SUCNR1), cathelicidin antimicrobial peptide (CAMP), and cathepsin G 
(CTSG). Similar observations were made in putative canine M-MDSCs, which expressed transcripts encoding 
the calcium-binding proteins S100A8 and S100A12 at high levels compared to C MONOs, in addition to tet-
raspanin 2 (TSPAN2), IL1 receptor 2 (IL1R2), and IL4 receptor (IL4R) (Fig. 3d). Of interest, the respective PMN 
and MONO populations showed a number of differentially expressed genes when comparing tumor-bearing and 
healthy dogs (Supplementary Figs S2A–S2D).
Ingenuity Pathway Analysis was performed on all differentially expressed genes in PMN-MDSCs compared 
to C PMNs with an absolute FC ≥ 2 and FDR ≤ 0.05. Two pathways were found to be positively enriched in 
PMN-MDSCs, eukaryotic initiation factor 2 (EIF2) signaling and peroxisome proliferator-activated receptor 
(PPAR) signaling, while numerous pro-inflammatory pathways were negatively represented (Fig. 4).
Taken together, these findings substantiated our view that these hypodense myeloid populations were indeed 
MDSC subsets that were distinct from the comparative conventional cells.
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Figure 2. Canine CADO48A+ myeloid cells exhibit T cell suppression. (a) Exemplar of Ki-67 incorporation 
in CD5+CD8+ cells after PBMCs were co-cultured alone or 1:1 with H PMNs, C PMNs, and PMN-MDSCs for 
72 hours. Exemplar depicts results using PBMCs from one healthy control dog. (b) Summary of proliferation 
assay results using cells isolated from five tumor-bearing dogs (normalized to PBMCs alone, average of co-
culture results with two different healthy PBMCs). Top: Mean proportion of T cells that are Ki67+ [+ as 
superscript], with each line identifying C PMNs and PMN-MDSCs from the same tumor-bearing dog, as well 
the H PMNs used in that experiment. Bottom: Box-and-whisker plots depicting arithmetic mean values (dots) 
for all experiments. In each case, the box shows the respective 25th and 75th percentiles, the line indicates 
the median value, and the whiskers stretch from the lowest to the highest data points still within 1.5 times the 
interquartile range of the respective lower and upper quartiles. A letter indicates a significant difference for that 
comparison (p < 0.01).
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Figure 3. Canine MDSC subsets are characterized by distinct transcriptomic signatures. (a) Principal 
component analysis depicting transcriptional similarities of the different cell populations (demarcated by 
colors) and whether the sample came from a healthy (circle) or tumor-bearing (triangle) dog. Each symbol 
indicates one dog. The ellipse summarizes each cell subtype grouping using the multivariate t-distribution. PC1 
accounted for 63.8% of all variance, while PC2 accounted for 8.22% of all variance. (b) Heatmap comparing 
transcriptional signatures across the 6 different cell populations, using the 1-Spearman rank correlation 
metric. Red indicates positive enrichment, and blue indicates negative enrichment. Increased vertical length 
of the dendrogram is inversely proportional to similarity between the cell types. (c,d) Volcano plot depicting 
differentially expressed genes in PMN-MDSCs relative to C PMNs (c) and putative M-MDSCs relative to 
C MONO MONOs (d). The red line indicates a significant FDR. Each dot represents one gene, and genes 
previously associated with MDSC function or novel but strongly upregulated genes are labeled in red.
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Cross-species analysis of PMN-MDSCs identifies a conserved gene signature. Focusing on the more 
numerous PMN-MDSC population, for which we had functional data, we next formally assessed the degree of sim-
ilarity of the respective canine, human, and murine cells of this phenotype. We did not perform parallel analyses for 
our putative M-MDSC population since we have not yet validated their identity by T cell suppression assays.
We compared our canine RNA-Seq data with those previously published on human and murine PMN-MDSCs. 
For all three species, genes differentially expressed by PMN-MDSCs compared to C PMNs were ordered accord-
ing to the FDR of their expression, using only those genes that were detected in all three species. The resulting lists 
for each species were then analyzed for similarity. The signatures of the top 500 differentially expressed genes were 
statistically similar between canine and human PMN-MDSCs (Fig. 5a), but no such pattern was observed when 
this same list of genes were compared between canine and murine PMN-MDSCs (Supplementary Fig. S3A,B). 
To further understand the similarity between canine and human PMN-MDSCs, we identified those genes differ-
entially expressed by PMN-MDSCs in comparison to C PMNs of both species with a FC ≥ 2. A comparison of 
these two lists identified 44 genes, including MPO, ELANE, as well as numerous ribosomal proteins (Fig. 5b and 
Supplementary Fig. S3C). Pathway analysis of these 44 genes highlighted six enriched pathways in PMN-MDSCs, 
including EIF2 signaling and TREM1 signaling (Supplementary Fig. S3D).
A comparison of those genes differentially expressed by PMN-MDSCs compared to C PMNs of dogs, humans 
and mice revealed five genes shared by all three species (Fig. 5c) – MMP8, LTF, LCN2, EPB41L3, and CAMP – 
four of which had not previously been implicated in PMN-MDSC function. A comparison of the FC expression 
in each species for these five genes, both in the respective transcriptomic datasets – including our own RNA-Seq 
dataset – and confirmatory RT-qPCR assays, revealed broad concordance (Fig. 5d and Supplementary Fig. S3E).
Discussion
Pet dogs with spontaneous tumors have contributed to the development of a variety of therapies used in human 
medicine11. Their outbred nature, larger size, presence of an intact immune system, and exposure to environmen-
tal factors shared with humans makes them an attractive model to better understand cancer development, pro-
gression, and treatment11,13. Although previous studies in dogs with spontaneous tumors have identified MDSCs, 
these studies did not differentiate between the two established subsets of MDSCs15,16. Our study therefore set out 
to characterize the cellular and molecular phenotype of PMN-MDSCs and M-MDSCs in dogs, with the ultimate 
aim of better understanding these two cell populations and their role in cancer.
We identified myeloid populations in canine peripheral blood resembling both murine and human MDSCs, 
using a gating schema similar to that used to identify these cells in humans4,6,33. The lack of availability of 
canine-specific or validated cross-reactive mAb against CD15, CD66b and/or LOX-1 in dogs at the time of the 
current study precluded the use of these markers in our panel for PMN-MDSCs. Nevertheless, we were able to 
Positive Z-score Negative Z-score Ratio
Figure 4. Canine PMN-MDSC transcriptomic signatures show enrichment of immune-related pathways. 
Ingenuity Pathway Analysis (IPA) of differentially expressed genes in PMN-MDSCs relative to C PMNs. Only 
those genes with a |FC| ≥ 2 and FDR ≤ 0.05 were imported into IPA. Greater color intensity correlates with 
stronger enrichment of Z-score, positive (orange) or negative (blue). Ratio refers to the proportion of genes 
represented in our data set relative to all known genes in IPA’s database for a given pathway.
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capitalize on the availability of a validated mAb used to identify PMNs in dogs38, which we substituted as a senti-
nel for CD15. This mAb was also used in one of the two original reports describing MDSCs in dogs16. The hypo-
dense myeloid cells isolated using this mAb clearly resembled PMN-MDSCs by light and electron microscopy, 
thus lending support to their identity as PMN-MDSCs. In the case of M-MDSCs, the availability of a validated 
cross-reactive mAb against canine CD1439 facilitated the identification of this subset in a directly comparable 
manner to that of human M-MDSCs. Given that CD14 may also be expressed by non-myeloid cells40, we con-
sidered it important to adopt a cascaded gating approach focusing only on CD5−CD21−CD11b+ cells in our 
analyses. Electron microscopic images added additional weight to the putative identity of the MDSC subsets, 
demonstrating greater ER dilation than the respective conventional cells17. Further confirmation of the identify 
of these subsets came from our downstream transcriptomic studies.
Significantly higher frequencies of these MDSC subsets were documented in the peripheral blood of 
tumor-bearing dogs than healthy controls, showing parallels to findings in human patients41,42. Furthermore, 
bulkier tumors of a variety of histotypes were associated with higher frequencies of PMN-MDSCs – the more 
prevalent of the two populations in peripheral blood – concordant with the prevailing viewpoint that inflam-
matory signals generated in the tumor, which would broadly correlate with tumor size, drive the differentiation 
of MDSCs43,44. This phenomenon is also consistent with studies showing that tumor resection reduces45,46, and 
tumor recurrence increases47, MDSC frequency. Ultimate proof that the myeloid cells identified in our study 
were indeed PMN-MDSCs came with demonstration of their suppressive function, using a standard, polyclonal 
T cell suppression assay48. Variability of the suppression data reflected the clinical nature of samples, derived 
from individual dogs with various cancer histotypes. Moreover, PMN-MDSCs typically demonstrate only modest 
suppressive function that diminishes with age of sample in the context of polyclonal assays in vitro4,6, prompting 
our wish to streamline assays and minimize post-sorting delays before cells were put into culture. We therefore 
employed an assay whose readout was Ki-67 expression, which correlates with proliferation in multiple different 
contexts and shows greater sensitivity and ease of use than cell tracer dyes49,50. Furthermore, preliminary studies 
confirmed the close correlation between Ki-67 expression and dye dilution as metrics of T cell proliferation in 
our hands (data not shown).
Deeper analysis of the phenotype of the canine MDSC subsets by RNA-Seq yielded a number of interesting 
observations. Whether or not MDSCs are indeed a separate subset of cells has been a controversial topic in 
the field for a number of years2,4. Our transcriptomic findings suggested that they possess distinct molecular 
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Figure 5. Cross-species comparisons of PMN-MDSCs highlight common transcriptomic signatures across 
three mammalian taxa. (a) Similarity score (square) and p-value (circle) are graphed using the top 100–500 
canine and human PMN-MDSC differentially expressed genes input into the ‘OrderedList’ R program. Dashed 
line indicates p = 0.05, and up to the top 500 genes are statistically similar in both species. (b,c) Venn diagram 
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comparing the fold change of the five conserved genes across the three species.
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signatures, as shown by PCA and heatmaps of the respective populations. The canine MDSCs showed increased 
expression of a number of canonical genes implicated in MDSC function. For example, PMN-MDSCs produce 
reactive oxygen and nitrogen species51,52: in line with these characteristics, the canine PMN-MDSCs showed 
greater abundance of transcripts encoding NOS2, NOX2, and MPO than PMNs from the same patient3,51,53. 
COX1, which mediates the synthesis of prostaglandins and has been implicated in MDSC development54,55, was 
also differentially represented in canine PMN-MDSCs, as were PTGS1 and PTGER2. Furthermore, transcripts 
encoding the matrix metalloproteases MMP8 and MMP9 were differentially expressed by canine PMN-MDSCs. 
Functioning in degrading the extracellular matrix, these enzymes mediate the release of vascular endothelial 
growth factor (VEGF) to promote new vessel development and metastasis56,57. Interestingly, the transcript encod-
ing CD177, a PMN marker58,59 expressed on the surface of MDSCs as well as MDSC exosomes60, was also dif-
ferentially expressed by canine PMN-MDSCs. This observation prompted consideration of CD177 as a marker 
to distinguish canine PMN-MDSCs from PMNs. Increased expression of CXCL17 by PMN-MDSCs was also of 
interest, as previous studies have implicated CXCL17 in the recruitment of MDSCs and poor prognosis in human 
cancer patients61,62. Another differentially expressed transcript, SUCNR1, has been implicated in prostaglandin 
synthesis and promotion of an anti-inflammatory phenotype in a model of multiple sclerosis63; a similar mech-
anism may be at play in PMN-MDSCs. On the other hand, putative M-MDSCs showed greater abundance of 
transcripts encoding both the IL4R, consistent with previous data8,64, and S100A8, serum concentrations of which 
have been associated with poor cancer survival36,65–67. IL1R2 was also of interest, as it has previously been impli-
cated in the transcription of IL-6 and VEGF, promoting angiogenesis68. Putative canine M-MDSCs differentially 
expressed transcripts encoding thrombospondin 1 (THBS1), another protein implicated in MDSC migration60, 
and TPSAN1, which has been implicated in cell invasion and motility in tumor cells69. Whether high expression 
of TPSAN1 by M-MDSCs could promote tumor progression was an intriguing question. IPA revealed additional 
interesting insights. One of the two sole pathways enriched in canine PMN-MDSCs – EIF2 signaling – has been 
previously reported to be enriched in human MDSCs30 and is induced by ER stress30,70, concordant with our 
ultrastructural analyses of these cells. PPAR signaling, meanwhile, has been implicated in the recruitment and 
expansion of MDSCs by a variety of extrinsic mechanisms71, but intrinsic roles for this signaling axis in MDSCs 
have hitherto not been recognized. Nevertheless, this pathway has anti-inflammatory properties in myeloid cells 
in general72–74, speaking to a possible role in maintaining the suppressive status of MDSCs. In contrast to EIF2 and 
PPAR signaling, a number of pro-inflammatory pathways were less active in canine PMN-MDSCs than C PMNs, 
consistent with the prevailing view of MDSCs as immunosuppressive cells. Taken together, the canine transcrip-
tomic data therefore reconciled with previously published findings on these MDSC subsets in other species, while 
also revealing some novel avenues for future research.
Harnessing previously published transcriptomic data for humans and mice, we were surprised to discover that 
only the human and canine PMN-MDSCs had a significantly similar pattern of differentially expressed genes, 
adding support to the notion that the dog provides an attractive model for human cancer11,13,75,76. However, owing 
to the relative lack of available transcriptomic data in other species, these comparisons were made using only one 
human and one murine publication, both of which were based on gene microarray experiments. This difference 
in technical platform from our analysis had the potential to introduce bias into the comparisons, adding a note 
of caution to these preliminary findings. Nevertheless, using this published dataset to compare canine to human 
PMN-MDSCs identified 44 commonly upregulated genes. Importantly, pathway enrichment analysis using the 44 
shared genes highlighted six pathways that are enriched in PMN-MDSCs. Interestingly, the two pathways with the 
most significant activation states in our canine PMN-MDSCs (EIF2 signaling and TREM1 signaling) were also 
highly enriched in the 44 genes shared between the two species, emphasizing the importance of these pathways to 
MDSC function30,77. HIF1α has been implicated in the differentiation of MDSCs to suppressive tumor-associated 
macrophages78,79, while Gαi signaling is required for the activation of STAT380,81, an important transcription fac-
tor in PMN-MDSC development and function82,83. Representation of the colorectal cancer metastasis signaling 
pathway presumably reflects the importance of these cells to the dissemination of colorectal cancer84, but this 
notion remains speculative in the absence of more direct evidence. Enrichment of the phagosome maturation 
pathway was also interesting, because to the best of our knowledge it has not previously been associated with 
MDSC function. Phagocytosis is a well-established phenomenon in PMNs85, raising the important question of 
whether PMN-MDSCs also show phagocytic function, perhaps as an anti-microbial defense mechanism.
To further drill down on potential evolutionarily conserved mechanisms, we asked whether there were genes 
commonly upregulated in the PMN-MDSCs of all three species; five such genes were identified. Four of the 
five genes have not previously been implicated in PMN-MDSC function, and three of them – LTF, LCN2, and 
CAMP – play an important antimicrobial role86,87. LCN2 and LTF are both iron-binding proteins, raising the 
question of whether iron is important for MDSC suppressive function. Interestingly, LCN2 expands regulatory 
T cells88 and deactivates macrophages89, and LCN2 and LTF have been shown to play a protective role against 
oxidative stress90,91. Furthermore, LTF has been shown to inhibit neutrophil and eosinophil migration92,93. These 
novel observations, made by leveraging the power of evolution, therefore raise the intriguing possibility that 
PMN-MDSCs serve a hitherto unrecognized role in anti-microbial defenses, and/or have co-opted conserved 
antimicrobial peptides to serve immunoregulatory functions to promote tumor growth. In synopsis, both indi-
vidual genes and evolutionarily conserved pathways shape the view that canine PMN-MDSCs show striking 
similarities to those of other mammalian species, but also raise important new questions about the functional 
breadth and versatility of these intriguing cells.
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